206 related articles for article (PubMed ID: 16421596)
21. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.
Tanaka K; Iwamoto S; Gon G; Nohara T; Iwamoto M; Tanigawa N
Clin Cancer Res; 2000 Jan; 6(1):127-34. PubMed ID: 10656440
[TBL] [Abstract][Full Text] [Related]
22. Expression of cytokeratin markers, ER-alpha, PR, HER-2/neu, and EGFR in pure ductal carcinoma in situ (DCIS) and DCIS with co-existing invasive ductal carcinoma (IDC) of the breast.
Steinman S; Wang J; Bourne P; Yang Q; Tang P
Ann Clin Lab Sci; 2007; 37(2):127-34. PubMed ID: 17522367
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value of Survivin and Livin in nasopharyngeal carcinoma.
Xiang Y; Yao H; Wang S; Hong M; He J; Cao S; Min H; Song E; Guo X
Laryngoscope; 2006 Jan; 116(1):126-30. PubMed ID: 16481824
[TBL] [Abstract][Full Text] [Related]
24. Survivin and COX-2 expression in male breast carcinoma.
Younis T; Haché KD; Rayson D; Dewar R; Gray S; Barnes PJ
Breast; 2009 Aug; 18(4):228-32. PubMed ID: 19632843
[TBL] [Abstract][Full Text] [Related]
25. The prognostic significance of COX-2 and survivin expression in ovarian cancer.
Athanassiadou P; Grapsa D; Athanassiades P; Gonidi M; Athanassiadou AM; Tsipis A; Patsouris E
Pathol Res Pract; 2008; 204(4):241-9. PubMed ID: 18171606
[TBL] [Abstract][Full Text] [Related]
26. Stromal architecture and periductal decorin are potential prognostic markers for ipsilateral locoregional recurrence in ductal carcinoma in situ of the breast.
Van Bockstal M; Lambein K; Gevaert O; De Wever O; Praet M; Cocquyt V; Van den Broecke R; Braems G; Denys H; Libbrecht L
Histopathology; 2013 Oct; 63(4):520-33. PubMed ID: 23889174
[TBL] [Abstract][Full Text] [Related]
27. High nuclear expression of the apoptosis inhibitor protein survivin is associated with disease recurrence and poor prognosis in laryngeal basaloid squamous cell carcinoma.
Marioni G; Ottaviano G; Marchese-Ragona R; Giacomelli L; Bertolin A; Zanon D; Marino F; Staffieri A
Acta Otolaryngol; 2006 Feb; 126(2):197-203. PubMed ID: 16428200
[TBL] [Abstract][Full Text] [Related]
28. Expression of survivin and its clinicopathological correlations in invasive ductal carcinoma of the breast.
Al-Joudi FS; Iskandar ZA; Hasnan J; Rusli J; Kamal Y; Imran AK; Ahmed M; Zakaria J
Singapore Med J; 2007 Jul; 48(7):607-14. PubMed ID: 17609820
[TBL] [Abstract][Full Text] [Related]
29. Survivin expression correlates with unfavourable prognoses in invasive ductal carcinoma of the breast.
Al-Joudi FS; Iskandar ZA; Imran AK
Med J Malaysia; 2007 Mar; 62(1):6-8. PubMed ID: 17682561
[TBL] [Abstract][Full Text] [Related]
30. Expression of E-cadherin in human ductal breast cancer carcinoma in situ, invasive carcinomas, their lymph node metastases, their distant metastases, carcinomas with recurrence and in recurrence.
Jeschke U; Mylonas I; Kuhn C; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2007; 27(4A):1969-74. PubMed ID: 17649807
[TBL] [Abstract][Full Text] [Related]
31. Docosahexaenoic acid induces proteasome-dependent degradation of beta-catenin, down-regulation of survivin and apoptosis in human colorectal cancer cells not expressing COX-2.
Calviello G; Resci F; Serini S; Piccioni E; Toesca A; Boninsegna A; Monego G; Ranelletti FO; Palozza P
Carcinogenesis; 2007 Jun; 28(6):1202-9. PubMed ID: 17183061
[TBL] [Abstract][Full Text] [Related]
32. Histopathological and cell biological characteristics of ductal carcinoma in situ (DCIS) of the breast-a comparison between the primary DCIS and subsequent ipsilateral and contralateral tumours.
Idvall I; Ringberg A; Anderson H; Akerman M; Fernö M
Breast; 2005 Aug; 14(4):290-7. PubMed ID: 16085235
[TBL] [Abstract][Full Text] [Related]
33. Immunohistological localisation of human FAT1 (hFAT) protein in 326 breast cancers. Does this adhesion molecule have a role in pathogenesis?
Kwaepila N; Burns G; Leong AS
Pathology; 2006 Apr; 38(2):125-31. PubMed ID: 16581652
[TBL] [Abstract][Full Text] [Related]
34. Relationship between nuclear grade of ductal carcinoma in situ and cell origin markers.
Tang P; Wang X; Schiffhauer L; Wang J; Bourne P; Yang Q; Quinn A; Hajdu SI
Ann Clin Lab Sci; 2006; 36(1):16-22. PubMed ID: 16501232
[TBL] [Abstract][Full Text] [Related]
35. Phenotypic alterations in ductal carcinoma in situ-associated myoepithelial cells: biologic and diagnostic implications.
Hilson JB; Schnitt SJ; Collins LC
Am J Surg Pathol; 2009 Feb; 33(2):227-32. PubMed ID: 18936688
[TBL] [Abstract][Full Text] [Related]
36. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
37. Breast cancer-specific mortality after invasive local recurrence in patients with ductal carcinoma-in-situ of the breast.
Lee LA; Silverstein MJ; Chung CT; Macdonald H; Sanghavi P; Epstein M; Holmes DR; Silberman H; Ye W; Lagios MD
Am J Surg; 2006 Oct; 192(4):416-9. PubMed ID: 16978940
[TBL] [Abstract][Full Text] [Related]
38. Margin width as the sole determinant of local recurrence after breast conservation in patients with ductal carcinoma in situ of the breast.
Macdonald HR; Silverstein MJ; Lee LA; Ye W; Sanghavi P; Holmes DR; Silberman H; Lagios M
Am J Surg; 2006 Oct; 192(4):420-2. PubMed ID: 16978941
[TBL] [Abstract][Full Text] [Related]
39. Local recurrences after conservative treatment of ductal carcinoma-in-situ of the breast without radiotherapy: the effect of age.
Schouten van der Velden AP; Peeters PH; Koot VC; Hennipman A
Ann Surg Oncol; 2006 Jul; 13(7):990-8. PubMed ID: 16788762
[TBL] [Abstract][Full Text] [Related]
40. Histological markers that predict clinical recurrence in ductal carcinoma in situ of the breast: an Australian population-based study.
Provenzano E; Hopper JL; Giles GG; Marr G; Venter DJ; Armes JE
Pathology; 2004 Jun; 36(3):221-9. PubMed ID: 15203725
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
